Abbott Laboratories (ABT)
 NYSE: ABT · Real-Time Price · USD
 123.64
 -1.03 (-0.83%)
  Oct 31, 2025, 10:17 AM EDT - Market open
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $11.37B in the quarter ending September 30, 2025, with 6.90% growth. This brings the company's revenue in the last twelve months to $43.84B, up 6.37% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm) 
 $43.84B
Revenue Growth 
 +6.37%
P/S Ratio 
 4.95
Revenue / Employee 
 $384,588
Employees 
 114,000
Market Cap 
214.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% | 
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% | 
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% | 
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% | 
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
ABT News
- 21 hours ago - Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV - GlobeNewsWire
- 2 days ago - Best Dividend Kings: October 2025 - Seeking Alpha
- 10 days ago - Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports - Reuters
- 13 days ago - Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming - Seeking Alpha
- 14 days ago - These Analysts Revise Their Forecasts On Abbott Following Q3 Results - Benzinga
- 14 days ago - Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds - Seeking Alpha
- 15 days ago - Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Benzinga
- 15 days ago - Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript - Seeking Alpha